Houston Biotechnology, Santen deal

Santen received an exclusive option to enter into a Japanese co-development and license agreement covering HBI's 4197X-RA Immunotoxin to prevent the formation of secondary cataract. Santen paid $250,000 for the option, which expires Dec. 21. If exercised, the agreement may provide HBI with up to $7.8 million in R&D support over the next six years. ...